Exchange: NASDAQ·Updated 07:56 PM EDT
News
all
press releases
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.
Stocktwits
More News
Twist Bioscience Stock Resilient Despite Scorpion Capital Short Report
TWST shares surge after Anthropic names the company an independent evaluator in a new AI-driven protein design campaign. The bullish momentum overshadows a critical short report published on X by activist short-seller Scorpion Capital.read more...
Benzinga
Twist Bioscience Stock Hits 52-Week High - Here's Why
Twist Bioscience (TWST) stock jumped 17% after Anthropic chose the firm to test AI-designed proteins. Get the full market update.read more...
Benzinga
‘Pharma Bro’ Martin Shkreli Slams Anthropic’s Claude Drug-Discovery Claims: ‘This Is Not Impressive Work’
Claude-designed proteins successfully bound to 14 of 15 targets in independent testing by Adaptyv Bio and Twist Bioscience.
Stocktwits
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
Twist Bioscience Corporation (Nasdaq: TWST) (Twist), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sold...
Business Wire
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
Twist Bioscience Corporation (Nasdaq: TWST) (Twist), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up...
Business Wire
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (Twist or the Company), a mid-cap growth and value biotech company, today announced that a total of 44,434 restricted stock units (RSUs) will be granted to 24 recently hired individuals, in each case as...
Business Wire
Twist Bioscience Sees AI Drug Discovery Pipeline Expand
Twist Bioscience (NASDAQ: TWST) stock is up on strong Q3 results and raised guidance. AI drug discovery and NGS businesses show growth.read more...
Benzinga
Twist Bioscience (TWST) Reports Q3 Loss, Beats Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of -12.00% and +3.39%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the third quarter fiscal 2026 ended June 30, 2026. Visit the Events and Presentations page of the Investor Relations section under the Company tab...
Business Wire

Advertisement|Remove ads.